Yürüyen Araştırmalar

Prevalence and Clinical Associates of Iron Deficiency in Patients with Atrial Fibrillation (AID-IF)

Dilek Ural

Yeni Tani Almis Evre 3 Veya Evre 4 Over, Fallop Tupu Veya Primer Peritoneal Kanserli Hastalarda Atezolizumabin Plaseboya Karsi Paklitaksel, Karboplatin Ve Bevasizumabla Kombinasyon Halinde Uygulanmasina Yonelik Calisma

Çağatay Taşkıran

SELECT-Semaglutid molekülünün fazla kilolu veya obeziteli bireylerde kardiyovasküler sonuçlar üzerine etkileri

Dilek Yazıcı

Armor

Nonalkolik Steatohepatit'li (NASH) Hastalarda Aramchol'ün Etkililiğinin ve Güvenliliğinin Değerlendirildiği Faz 3/4, Çok Uluslu, Çok Merkezli, Çift Kör, Plasebo-Kontrollü Bir Klinik Çalışma (ARMOR Çalışması)

Murat Akyıldız

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

Cihan Yuradydın

Over Kanseri Hastalarında Ön Basamak Platin Bazlı Kemoterapiye Yanıtın Ardından İdame Tedavisi Olarak Rukaparib ve Nivolumabı Değerlendiren Çok Merkezli, Randomize, Çift Kör, Plasebo Kontrollü Faz 3 Çalışma

Çağatay Taşkıran

M141184 Troia

Solid Tümörü Olan Hastalarda Hibrit Yakalama Temelli Kapsamlı Genomik Profillemenin (CGP) Tedavi Stratejileri ÛzerindekivEtkisinin Belirlenmesi: Ulusal, Çok Merkezli, Retrospektif Bir Çalışma M141184

Fatih Selçukbiricik

12 Yaş ve Üzeri Wilson Hastalarında Standart Tedaviye Karşı 48 Hafta Boyunca Uygulanan ALXN1840’ın Etkililik ve Güvenliliğinin Değerlendirildiği, En Fazla 60 Aylık Uzatma Dönemine Sahip Faz 3, Randomize, Değerlendiricinin Körlendiği, Çok Merkezli Çalışma

Murat Akyıldız

PEX-ROTEM

Psödoeksfoliasyon sendromlu hastalarda hiperkoagülabilitenin tanısal ve prognostik göstergelerinin belirlenmesi

Afsun Şahin

2018.048.IRB2.011

Otoimmün nörolojik hastalıklarda immünopatogenezin ve klinik özelliklerle ilişkili immünolojik parametrelerin araştırılması

Atay Vural

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

Oğuzhan Deyneli

LRRK2 International Parkinson’s disease project (LIPAD)

Özgür Öztop Çakmak

An Open-label, Ascending Multiple-dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

Şükrü Hatun

NEXRPS01

Radikal Prostatektomi Sonrası Erkeklerde Gelişen Hafif veya Orta Dereceli İdrar Kaçırma Tedavisinde Duloksetinin Etkinliğinin ve Güvenliliğinin Araştırılması: Faz III Randomize Çalışma Protokol No: NEXRPS01

Tufan Tarcan

A multicenter, open-label, two-step, phase Ia/Ib study of tumor-targeted prodrug RS-0139 in patients with recurrent, locally advanced or metastatic non-small cell lung cancer (NSCLC)

Hakan Orer

A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE)

Murat Akyıldız

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)

Fatih Selçukbiricik

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

Fatih Selçukbiricik

A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

Fatih Selçukbiricik

A Phase II, Randomized, Double-Blind Placebo-Controlled Study Of Atezolizumab With Or Without Bevacizumab In Combination With Cisplatin Plus Gemcitabine In Patients With Untreated, Advanced Biliary Tract Cancer

Fatih Selçukbiricik

The PULSTA™ Transcatheter Pulmonary Valve (TPV) Pre-Approval Study

Ender Ödemiş

A Phase 1, Randomized, Double-Blind, Placebo- Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients with Nonalcoholic Steatohepatitis (NASH)

Murat Akyıldız

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors

Nil Molinas

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)

Ayşe Bilge Öztürk

ONMUS

Oral Nütrisyonel Destek Alan Gastrointestinal Sistem Kanser Hastalarında Oral Nütrisyonel Desteğin Kas Fonksiyonuna Etkilerinin Değerlendirildiği Çok Merkezli Gözlemsel Çalışma (OnMuS)"

Fatih Selçukbiricik

A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficact And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors

Fatih Selçukbiricik

A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Evaluate The Efficacy, Safety, And Antiviral Activity Of Ro7496998 (At-527) In Patients With Mild Or Moderate Covid-19

Önder Ergönül

A Multicenter, Observational, 6-Month Follow-Up Study Of Patients With Covid-19 Previously Enrolled In A Ro7496998 (At-527) Study

Önder Ergönül

GP2

The Global Parkinson’s Genetics Program (GP2)

Sibel Ertan

MJFF

MJFF The Global Parkinson’s Genetics Program

Sibel Ertan

Epidemiological Study In Frontotemporal Dementia

Sibel Ertan

20510

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.

Onur Demirkol

Randomized, Double-Blind, Placebo-Controlled Study Of Regn4461, A Leptin Receptor Agonist Antibody, In Patients With Generalized Lipodystrophy

Oğuzhan Deyneli

Yeni Tanı Konulmuş, İleri Evre, Seröz veya Endometrioid Yumurtalık, Primer Periton ve/veya Fallop Tüpü Kanseri Olan Kadınlarda Homolog Rekombinasyon Eksikliğinin Prevalansını Belirlemeye Yönelik Kesitsel, Girişimsel Olmayan, Çok Merkezli Bir Çalışma

Çağatay Taşkıran

A Randomised, Double-blind, Placebocontrolled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)

Fatih Selçukbiricik

A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Fulden Yumuk

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy And Safety Of Mosunetuzumab In Combination With Lenalidomide In Comparison To Rituximab In Combination With Lenalidomide In Patients With Follicular Lymphoma After At Least One Line Of Systemic Therapy

Meltem Akay